185 results about "Butylphthalide" patented technology

The invention discloses a method for simultaneously and quantitatively detecting ligustilide and senkyunolide A. The method comprises the following steps: according to an HPLC (high performance liquid chromatography) method in which butylphthalide serves as a substitution reference substance and octadecyl silane bonded silica gel serves as a filling agent, respectively determining the peak area Ax and the peak area Ay of the ligustilide (X) and the senkyunolide A (Y) in a to-be-detected sample by using a single wavelength in a range of 275-284nm; and according to the concentration Cz and the peak area Az of the substitution reference substance, namely the butylphthalide (Z), calculating the concentration C of the detected components, namely the ligustilide and the senkyunolide A, according to a formula by using correction factors f, wherein a correction factor fx is within 0.20-0.25, and a correction factor fy is within 0.46-0.54. A detection result obtained by using the method provided by the invention is stable, and is in accordance with a detection result obtained by using a method in which the ligustilide and the senkyunolide A, freshly prepared, serve as reference substances, and the problems that the dual-wavelength detection needs to be simultaneously adopted, the requirements on HPLC equipment are high and the universality is poor in the prior art are solved.

The invention relates to a polymerization inhibitor for preventing self-polymerization or co-polymerization of C5 diolefins, which comprises composition A: diethylhydroxylamine, composition B: tert-butyl pyrocatechol, and solvent, wherein the solvent is selected from benzene, toluene, dimethylbenzene or ethylbenzene, the weight ratio of the composition A and the composition B being (0.5-6):1, the total content of the composition A and the composition B in the polymerization inhibitor being 25-45wt%. Compared with the prior art, the invention can realize better polymerization inhibiting effect, and no extra separation process is needed in the current C5 distillate separation procedure.

A pharmaceutical composition comprising butylphthalide and borneol is disclosed. The pharmaceutical composition has synergistic effects on treating cerebrovascular diseases especially ischemic cerebrovascular diseases, and is capable of obviously enhancing treating effects of the butylphthalide, reducing the effective dose of the butylphthalide, and reducing the using amount. Untoward effects of the pharmaceutical composition during long-term application can be reduced.

The invention provides a process for preventing self-polymerization or co-polymerization of C5 diolefins in separation process of petroleum C5 distillate, which consists of charging polymerization inhibitor into C5 distillate material, and making the polymerization inhibitor maintain a finite amount in the C5 distillate material, the polymerization inhibitor comprises composition A: diethylhydroxylamine, and composition B: tert-butyl pyrocatechol, the weight ratio of the composition A and the composition B being (0.5-6):1, the quantity of polymerization inhibitor in the C5 distillate material is sustained at 30-600ppm calculated on the total amount of the composition A and the composition B. The invention can realize better polymerization inhibiting effect, and no extra separation process is needed in the current C5 distillate separation procedure.

The invention relates to the field of medicine, in particular to a pharmaceutical composition containing butylphthalide and a novel solubilizer to improve the water solubility of butylphthalide by means of the novel solubilizer, clinically required solid form, or semisolid form or liquid form of butylphthalide is developed, so that the treatment effect of butylphthalide can be better realized. The composition can be used for preparing various drug forms such as tablets, capsules, particles, powder, ointment, cream, gel, infusion, squirt cut, powder filling and oral liquid. Compared with the prior art, the pharmaceutical composition is better in safety performance and water solubility of butylphthalide.